Original Article
Glycogen Storage Diseases Presenting as Hypertrophic Cardiomyopathy
N Engl J Med 2005; 352:362-372January 27, 2005
- Abstract
Background
Unexplained left ventricular hypertrophy often prompts the diagnosis of hypertrophic cardiomyopathy, a sarcomere-protein gene disorder. Because mutations in the gene for AMP-activated protein kinase γ2 (PRKAG2) cause an accumulation of cardiac glycogen and left ventricular hypertrophy that mimics hypertrophic cardiomyopathy, we hypothesized that hypertrophic cardiomyopathy might also be clinically misdiagnosed in patients with other mutations in genes regulating glycogen metabolism.
Methods
Genetic analyses performed in 75 consecutive unrelated patients with hypertrophic cardiomyopathy detected 40 sarcomere-protein mutations. In the remaining 35 patients, PRKAG2, lysosome-associated membrane protein 2 (LAMP2), α-galactosidase (GLA), and acid α-1,4-glucosidase (GAA) genes were studied.
Results
Gene defects causing Fabry's disease (GLA) and Pompe's disease (GAA) were not found, but two LAMP2 and one PRKAG2 mutations were identified in probands with prominent hypertrophy and electrophysiological abnormalities. These results prompted the study of two additional, independent series of patients. Genetic analyses of 20 subjects with massive hypertrophy (left ventricular wall thickness, ≥30 mm) but without electrophysiological abnormalities revealed mutations in neither LAMP2 nor PRKAG2. Genetic analyses of 24 subjects with increased left ventricular wall thickness and electrocardiograms suggesting ventricular preexcitation revealed four LAMP2 and seven PRKAG2 mutations. Clinical features associated with defects in LAMP2 included male sex, severe hypertrophy, early onset (at 8 to 17 years of age), ventricular preexcitation, and asymptomatic elevations of two serum proteins.
Conclusions
LAMP2 mutations typically cause multisystem glycogen-storage disease (Danon's disease) but can also present as a primary cardiomyopathy. The glycogen-storage cardiomyopathy produced by LAMP2 or PRKAG2 mutations resembles hypertrophic cardiomyopathy but is distinguished by electrophysiological abnormalities, particularly ventricular preexcitation.
Media in This Article
Figure 1
Glycogen-Associated Cardiomyopathy in Families with LAMP2 and PRKAG2 Mutations.Figure 2
Histopathological Findings in Cardiac Tissue from a Patient with a LAMP2 Mutation.Article Activity
- Article
Hypertrophic cardiomyopathy, an autosomal dominant disorder associated with increased morbidity and premature mortality, is traditionally diagnosed on the basis of increased cardiac mass with histopathological findings of myocyte enlargement, myocyte disarray, and cardiac fibrosis.1-3 However, given the availability of sophisticated noninvasive imaging techniques, an echocardiographic demonstration of unexplained left ventricular hypertrophy constitutes the current basis for a diagnosis of hypertrophic cardiomyopathy.3 Echocardiography has shown that there is considerable diversity in the manifestations of hypertrophic cardiomyopathy, including variable age at onset, from early childhood to late adulthood, and severity of left ventricular hypertrophy. Left ventricular wall thickness in hypertrophic cardiomyopathy can vary from slightly above normal to more than 50 mm (range, 13 to 60 mm), and massive hypertrophy (left ventricular wall thickness, ≥30 mm) is increasingly recognized as an important risk factor for sudden death.3,4
Sarcomere-protein gene mutations cause familial or sporadic hypertrophic cardiomyopathy and 15 percent of the cases of elderly-onset hypertrophic cardiomyopathy.5 To date, more than 200 mutations in 10 different genes are known.6 Molecular studies of patients with clinical features of hypertrophic cardiomyopathy but without sarcomere-protein gene defects have led to the identification of other genetic causes of cardiac hypertrophy, including mutations in PRKAG2, 7-9 the regulatory γ subunit of AMP-activated protein kinase. PRKAG2 mutations cause myocyte hypertrophy by stimulating glycogen-filled vacuoles but cause neither myocyte disarray nor interstitial fibrosis, which typically occur with defects of sarcomere-protein genes.9,10
Pathologic vacuoles containing glycogen or intermediary metabolites also occur in Pompe's disease (a recessively inherited lysosomal acid α-1, 4-glucosidase [GAA] deficiency), Danon's disease (an X-linked lysosome-associated membrane protein [LAMP2] deficiency), and Fabry's disease (an X-linked lysosomal hydrolase a-galactosidase A [GLA] deficiency).11-16 These multisystem disorders cause neuromuscular deficits, abnormal liver and kidney function, and abnormalities of the central nervous system as well as cardiac hypertrophy. Although some, atypical, patients with Fabry's disease have mild systemic manifestations and, predominantly, cardiac disease,11,17 the pleiotropic manifestations of Pompe's disease and Danon's disease rarely prompt the consideration of these disorders in the differential diagnosis of unexplained left ventricular hypertrophy.
We sequenced eight sarcomere-protein genes in 75 unrelated patients with hypertrophic cardiomyopathy in whom echocardiography showed unexplained left ventricular hypertrophy. Subsequent analyses of PRKAG2, LAMP2, GAA, and GLA in samples of patients who did not have a sarcomere-protein gene mutation revealed previously unidentified LAMP2 and PRKAG2 mutations. The clinical manifestations associated with these mutations prompted studies of two additional patient series: one involved subjects with massive hypertrophy, and one involved those with left ventricular hypertrophy plus electrophysiological defects.
Methods
Clinical Evaluations
Studies were performed in accordance with institutional guidelines for human research. The research protocol was reviewed and approved by the institutional review boards at the participating institutions, and written informed consent was obtained from all research subjects. Three independent series of patients were studied: one involving 75 consecutive subjects 12 to 75 years of age who had hypertrophic cardiomyopathy as diagnosed on the basis of echocardiograms showing unexplained left ventricular hypertrophy (wall thickness, ≥13 mm)3,18; one involving 20 subjects (9 to 58 years of age) with massive left ventricular hypertrophy (wall thickness, ≥30 mm) of unknown cause; and one involving 24 patients (8 to 42 years of age) with hypertrophic cardiomyopathy in whom electrocardiograms suggested the presence of ventricular preexcitation (a short PR interval, delta wave, or both).
Study subjects were from North America, South America, and Europe and identified themselves as white (86 percent), black (7 percent), or Hispanic (7 percent). Medical records, clinical evaluations, electrocardiograms, and echocardiograms were reviewed. Clinical studies that were performed before enrollment at the discretion of the referring cardiologist were included when available. After completion of genetic studies, cardiac evaluations were performed of family members carrying a mutation. Patients with LAMP2 mutations also underwent noninvasive neurologic and musculoskeletal evaluations and serum chemistry analyses. When available, pathological specimens were examined. All values are reported as means ±SD.
Genetic Studies
The genes encoding cardiac β-myosin heavy chain, cardiac myosin-binding protein C, cardiac troponin T, cardiac troponin I, cardiac actin, essential myosin light chain, regulatory myosin light chain, α-tropomyosin, and PRKAG2 were sequenced from genomic DNA as described previously.9,18 Exons 1 through 8, 9a, and 9b of LAMP2, exons 2 through 20 of GAA, and exons 1 through 7 of GLA were amplified with the use of the polymerase chain reaction (PCR) and sequenced and compared with GenBank accession numbers AC002476, NT_024915, and AL035422 with the use of primers available on the Internet (at http://genetics.med.harvard.edu/~seidman/). Sequence variants were confirmed by restriction-enzyme digestion. Variants that segregated with clinical status in family members and that were absent from 180 normal subjects who were matched with the subjects with hypertrophic cardiomyopathy for race or ethnic background (self-reported) were considered disease-causing mutations18,19 and were denoted by standard nomenclature.20 LAMP2 alleles were distinguished by single-nucleotide polymorphisms 156 A/T and 927 C/T, numbered according to complementary DNA (cDNA) (GenBank accession number NM_013995).
RNA was extracted with the use of Trizol (Invitrogen). We performed reverse transcription (RT) using a kit (One-Step RT-PCR, Qiagen) with primers available on the Internet (at http://genetics.med.harvard.edu/~seidman/).
Protein Analyses
Western blot analyses were performed in immunoprecipitation assay buffer with the use of 30 to 40 μg of protein lysates from lymphocytes or fibroblasts, as described previously,21 with polyclonal LAMP2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies (Santa Cruz Biotechnology).
Histopathological Analyses
Specimens were examined after staining with hematoxylin and eosin and LAMP2 immunohistochemistry. Electron-microscopical examinations of embedded tissue were performed after paraffin removal with the use of previously described procedures.9
Electrocardiography
Standard 12-lead electrocardiographic recordings were examined for ventricular preexcitation and left ventricular voltage (reported as the maximal S wave in V1 or V2 + maximal R wave in V5 or V6 [SV1 or SV2 + RV5 or RV6] or the maximal R or S deflection in any lead22).
Results
Seventy-five unrelated patients with hypertrophic cardiomyopathy (30 female and 45 male patients, 12 to 75 years of age at diagnosis) were prospectively enrolled for genetic analyses of sarcomere-protein mutations. Maximal left ventricular wall thickness ranged from 13 to 60 mm and in four persons exceeded 30 mm. In addition to typical electrocardiographic manifestations of hypertrophic cardiomyopathy,3,18 three persons had short PR intervals and three others had ventricular preexcitation patterns. Forty sarcomere-protein gene mutations were identified in these 75 patients.6,23 In the remaining 35 patients (27 of whom were male and 8 female), PRKAG2, LAMP2, GLA, and GAA sequences were analyzed. No mutations were identified in GLA or GAA sequences.
A previously undetected missense mutation — tyrosine to histidine at codon 487 — of PRKAG2 in Proband IP was associated with moderate hypertrophy (left ventricular wall thickness, 13 mm) and an extremely short PR interval (0.09 msec). LAMP2 mutations in which the sequence GTGA was deleted from the splice-donor site of intron 6 (IVS6+1_4delGTGA) and in which there was an A-to-G change in the splice-acceptor site of intron 6 (IVS6 –2A→G) in Probands CZ and FI were associated with severe hypertrophy (left ventricular wall thicknesses, 29 mm and 60 mm, respectively) and unusual electrocardiograms, with short PR intervals, short delta waves, or both, and extreme voltage, suggestive of ventricular preexcitation (Figure 1Figure 1
Glycogen-Associated Cardiomyopathy in Families with LAMP2 and PRKAG2 Mutations.). These clinical findings prompted the genetic studies of two additional patient series. LAMP2 and PRKAG2 sequences were determined in 20 patients with a left ventricular wall thickness of 30 mm or more; however, no mutations were identified. LAMP2 and PRKAG2 sequences were also determined in 24 probands with increased left ventricular wall thickness and electrocardiograms suggesting ventricular preexcitation. Seven PRKAG2 mutations9 and four LAMP2 mutations were identified, which corresponded to a mutation-detection rate of 46 percent in this group.LAMP2 Mutations
Six new LAMP2 mutations were detected — in Probands CZ, IP, LS, MFE, NR, and SS — that are predicted to alter substantially the lysosome-associated membrane protein, a 410-amino-acid molecule with a small cytoplasmic tail involved in receptor-mediated lysosomal uptake, and a large internal lysosome domain composed of highly glycosylated residues. One nonsense mutation (in Proband NR) signaled premature termination at amino acid 109. Five other mutations altered splice signals; the consequences of these alterations were assessed in the LAMP2 RNAs isolated from lymphocytes.
Mutation IVS1+1G→T (in Proband MFE) altered the intron 1 splice donor site; RNA maturation occurred by a cryptic splice site that excised 21 amino acids after the initiation codon. Mutation IVS1–2A→G (in Proband SS) altered the intron 1 splice-acceptor site; RNA deleted exon 2 residues and produced a frameshift mutation. Mutation IVS6+1_4delGTGA (in Proband CZ) altered the intron 6 splice-donor site and excised 41 codons. No mutant RNA was detected from mutation IVS6– 2A→G (in Proband FI) that altered the splice-acceptor site of intron 6, perhaps indicating that this defect triggered missense-mediated decay. Mutation 928G→A (in Proband LS) substituted isoleucine for valine (at residue 310), affected RNA processing, and hence produced a frameshift.
Expression of the mutant LAMP2 protein was assessed by Western blotting of protein extracts probed with antibodies to LAMP2 (Figure 2Figure 2
Histopathological Findings in Cardiac Tissue from a Patient with a LAMP2 Mutation.) and antibodies to GAPDH (data not shown). Protein extracts from the lymphocytes of Probands MFE and CZ (mutations IVS1+1G→T and IVS6+1_4delGTGA, respectively) contained a nearly full-length LAMP2 protein (100 kD), whereas protein extract from the lymphocytes and fibroblasts of Proband SS (mutation IVS1–2A→G) did not react with LAMP2 antibodies.Clinical Features in Probands with LAMP2 Mutations
Five of six probands with LAMP2 mutations were male. One proband had a family history of heart disease. None had mental retardation or overt neurologic or musculoskeletal deficits. Two male probands had histories of attention-deficit disorder and mild behavioral problems; both were taking psychoactive medications.
One asymptomatic proband came to medical attention because of an abnormal electrocardiogram. The other five probands presented with cardiac symptoms typically seen in hypertrophic cardiomyopathy, including chest pain, palpitations, syncope, and, in one, cardiac arrest. The onset of symptoms occurred between the ages of 8 and 15 years, younger than average for patients with mutations of the sarcomere-protein gene or PRKAG2 gene (33±17 years and 31±15 years, respectively) (Table 1Table 1
Cardiac Findings Associated with Mutations in Sarcomere-Protein Genes, PRKAG2, and LAMP2.).Echocardiography showed concentric left ventricular hypertrophy in all six probands; in five, left ventricular hypertrophy was massive. The average maximal left ventricular wall thickness was 35±15 mm (range, 20 to 60 mm) and significantly greater (P<0.01) than that typically found in patients with hypertrophic cardiomyopathy that is diagnosed on the basis of either clinical findings (average, 21 mm24) or genetic analyses (Table 1). Two probands (NR and SS) had substantial outflow tract gradients (55 and 65 mm Hg, respectively). Prominent right ventricular hypertrophy (wall thickness, ≥10 mm) was found without pulmonary disease in three probands. At the time of initial clinical presentation, all probands had normal left ventricular function and ejection fractions of 60 percent or more.
Twelve-lead electrocardiograms were strikingly abnormal in all probands. Left ventricular voltage was markedly increased and significantly greater (P<0.001) than in patients with sarcomere-protein gene mutations or PRKAG2 mutations (Table 1). In five probands, electrocardiograms showed ventricular preexcitation patterns with short PR intervals and delta waves (Figure 1B). Electrophysiological studies in three persons showed accessory atrioventricular connections; two had supraventricular arrhythmias, atrial fibrillation, or both, that required radiofrequency ablation.
The identification of LAMP2 mutations prompted analyses of serum chemistry. Creatine kinase and alanine aminotransferase levels were elevated by a factor of two or more in four of the six probands, and organ-specific enzyme isoforms indicated cardiac, musculoskeletal, and liver involvement. Serum levels of these enzymes were normal in the only female proband and in one male proband with a mosaic LAMP2 mutation.
Cardiac function progressively deteriorated during a six-year period in Family Member CZ III-1,25 and he died at the age of 22 years while awaiting heart transplantation. A pathological study of his heart (Figure 2A through 2D) showed marked cardiomegaly (weight, 1266 g) and diffuse hypertrophy. Histopathological examination showed myocyte hypertrophy and prominent interstitial fibrosis. Enlarged cardiomyocytes had extensive sarcoplasmic vacuolation with a spiderweb-like appearance; some had large, polymorphic, periodic acid–Schiff–positive perinuclear inclusions. LAMP2 antibodies reacted with the inclusions but lacked the lysosomal perinuclear granular pattern found in normal myocardium. Electron microscopy showed that some sarcoplasmic vacuoles were empty, without recognizable membranes, whereas other vacuoles contained inclusions consisting of amorphous, osmophilic, and focally granular material of variable density. Partially degraded vacuolar contents have been observed in specimens from persons with Danon's disease.12,15
LAMP2 Mutations in Family Members
In Families CZ and MFE, the X-linked LAMP2 mutation was maternally transmitted; one additional man (Family Member CZ III-2) and seven women also carried these LAMP2 mutations (Figure 1). Cardiac disease occurred only in Family Member CZ III-2. When he was 16 years old, his electrocardiogram showed prominent voltage and ventricular preexcitation. His echocardiogram from the same period was normal except for asynchronous contraction, which was attributed to preexcitation. Reevaluation at the age of 22 (after genetic diagnosis) demonstrated substantial hypertrophy and reduced function. He remains asymptomatic.
Although none of seven surviving female family members (14 to 46 years of age) with LAMP2 mutations had cardiac symptoms or abnormal cardiac studies, one woman (Family Member CZ I-2) died from congestive heart failure at the age of 44. She probably carried the LAMP2 mutation, given that both of her daughters are genetically affected and that her husband does not have cardiac disease (Family Member CZ-1).
No LAMP2 mutations were found in the family members of four probands. LAMP2 gene sequences were normal in the mothers of three affected male probands (SS, LS, and NR), and mitochondrial DNA polymorphisms confirmed biologic maternity (data not shown). Genetic studies of Proband LS demonstrated mosaicism: both mutant and wild-type LAMP2 sequences were identified despite a normal XY karyotype (not shown). Single nucleotide polymorphisms indicated that he had inherited the X chromosome and normal LAMP2 gene from his unaffected mother. One female proband (FI) with a normal karyotype also carried a LAMP2 mutation. Haplotype analyses (not shown) demonstrated that she had inherited one X chromosome from each genetically unaffected parent. We conclude that these LAMP2 mutations (in four probands: SS, LS, NR, and FI) arose spontaneously.
Discussion
Defects in the enzymes involved in the metabolism of muscle glycogen typically cause systemic disease26 and often involve the heart (Figure 3Figure 3
Principal Pathways of Glycogen Metabolism in Muscle.). Our study demonstrates that cardiac disease can be the initial and predominant manifestation of defects in human glycogen metabolism. Three of 75 persons in whom hypertrophic cardiomyopathy was diagnosed by echocardiography had cardiac-glycogen–storage disorders caused by LAMP2 or PRKAG2 mutations. These gene defects, like sarcomere-gene mutations, were associated with prominent left ventricular hypertrophy, but in addition, electrophysiological abnormalities were present.Family history, although informative in terms of sarcomere-protein gene and PRKAG2 mutations, was typically absent for patients with LAMP2 defects; these defects cause sporadic disease. Male sex, early onset of symptoms, marked or massive concentric left ventricular hypertrophy, prominent electrocardiographic voltages with ventricular preexcitation patterns (Figure 1), and asymptomatic elevations of serum-chemistry values further distinguished LAMP2 mutations from PRKAG2 or sarcomere-protein defects.
Previously reported LAMP2 mutations caused a variety of manifestations that are characteristic of Danon's disease.12-14 No probands in our series had clinically important neurologic disease, although psychological issues recognized in two young male subjects were attributed to attention-deficit disorder and an adolescent response to cardiac disease. None had overt muscle weakness, wasting, or myopathic symptoms; all had exercise restrictions because of the diagnosis of hypertrophic cardiomyopathy.
Gene dosage probably accounts for the different clinical consequences of X-linked LAMP2 mutations in men as compared with women, although unusual cardiac diseases were found in two female carriers of LAMP2 mutations. Perhaps X-inactivation sufficiently extinguished normal LAMP2 gene expression to contribute to or cause cardiomyopathy in female Proband FI and adult-onset heart failure in Family Members CZ I-2 and LO I-2 (Figure 1A). Gene dosage also contributed to clinical expression in men with identical LAMP2 mutations. During these studies, a male proband (LO in Figure 1A) with classical Danon's disease (mental retardation and musculoskeletal weakness, with protean findings on muscle biopsy) was referred for genetic analyses. Proband LO and his mother were found to have the same LAMP2 mutation (928G→A) as Proband LS, although these families are genetically unrelated (data not shown). Remarkably, Proband LO was hemizygous for the mutation, whereas mosaicism in Proband LS caused expression of both normal and mutant LAMP2 alleles. We presume that some normal LAMP2 protein in Proband LS accounted for the predominance of cardiac disease in comparison with multisystem Danon's disease in Proband LO.
The partial function of mutant LAMP2 proteins may also account for the cardiac form of Danon's disease, as compared with systemic Danon's disease. The musculoskeletal pathology of Danon's disease13,14 indicates a complete absence of LAMP2 immunoreactivity, whereas we found stable LAMP2 RNA and immunoreactive LAMP2 protein in lymphocytes from Probands CZ and MFE (Figure 2E). These mutant proteins may function sufficiently to limit disease in some, but not all, tissues.
Inclusion of LAMP2 and PRKAG2 mutations in the differential diagnosis of unexplained left ventricular hypertrophy is important for patient care. These mutations increase the risk of arrhythmias, as shown by preexcitation patterns on electrocardiograms, by accessory pathways on electrophysiological evaluation, and by patients' histories of supraventricular tachyarrhythmias, syncopal episodes, and sudden death. The mechanism for ventricular preexcitation is incompletely understood; however, a mouse model of one human PRKAG2 mutation shows disruption of the anulus fibrosus by glycogen-filled myocytes, thereby allowing atrioventricular activation that bypasses the atrioventricular node.10,27 Although LAMP2 mutations accumulate glycogen in lysosomes12 and PRKAG2 mutations accumulate glycogen throughout the myocyte,10 it is likely that there is a common mechanism for ventricular preexcitation in both glycogen-storage cardiomyopathies. We suggest that patients with unexplained left ventricular hypertrophy and preexcitation patterns on electrocardiograms undergo clinical and genetic evaluation for glycogen storage disease (Figure 4Figure 4
Algorithm for the Diagnostic Evaluation of Persons with Unexplained Left Ventricular Hypertrophy.).The different clinical courses associated with hypertrophic cardiomyopathy or glycogen storage cardiomyopathies underscore the importance of accurate diagnosis. Despite some increase in the risk of sudden death in patients with hypertrophic cardiomyopathy, the natural history of and treatment for sarcomere mutations are generally favorable: symptoms typically develop in early adulthood and increase slowly over many years; interventions that either alleviate outflow-tract obstruction or terminate arrhythmias, or both, improve long-term survival2,3,28; and progression to heart failure is uncommon (occurring in fewer than 10 percent of patients). Cardiomyopathy due to PRKAG2 mutations is also compatible with long-term survival, although progressive conduction-system disease may necessitate the implantation of a pacemaker and aggressive control of arrhythmias.7-9 By contrast, the prognosis associated with cardiomyopathy due to LAMP2 mutations is poor. The onset of disease during adolescence is followed by a rapid progression toward end-stage heart failure early in adulthood, often resulting in death.13,14
Although clinical evaluations may help to distinguish these disorders, genetic analyses can definitively establish the cause of unexplained left ventricular hypertrophy (Figure 4). This information is critical for determining the appropriate strategies of treatment and for defining genetic risk in family members. Applying the major advances in DNA sequencing to medicine has made gene-based diagnosis not only feasible, but a clinical reality.
Supported by the Howard Hughes Medical Institute and by the National Heart, Lung, and Blood Institute, National Institutes of Health.
We are indebted to Ms. Barbara A. McDonough, R.N., Ms. Susan A. Casey, R.N., Barbara A. Mostella, R.N., Dr. Brian W. Gross, and Dr. Eloisa Arbustini for their invaluable assistance in collecting clinical material and to Ms. Catherine M. Duffy, Ms. Susanne Bartlett, Mr. Howard Mulhern, and Mr. James Edwards for their technical assistance.
Source Information
From the Division of Cardiology, Brigham and Women's Hospital (M.A., C.E.S.), and the Department of Genetics, Harvard Medical School and Howard Hughes Medical Institute (M.A., J.M.G., C.E.S., J.G.S.) — all in Boston; the Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis (B.J.M.); the Department of Pediatrics, Division of Pediatric Cardiology, University of Alabama at Birmingham, Birmingham (W.H.J.); the Children's Heart Program of South Carolina, Medical University of South Carolina, Charleston (J.P.S.); the Department of Pathology, Children's Hospital and Harvard Medical School, Boston (A.R.P.-A.); the Department of Cardiology, Galleria de Genova, Genova, Italy (P.S.); the Children's Heart Clinic, Minneapolis (G.B.W.); and the Division of Pediatric Cardiology, Duke University Medical Center, Durham, N.C. (R.J.K.).
Address reprint requests to Dr. J.G. Seidman at the Department of Genetics, NRB Rm. 256, Harvard Medical School, 77 Ave. Louis Pasteur, Boston, MA 02115, or at seidman@genetics.med.harvard.edu.
- References
References
1
Maron BJ . Sudden death in young athletes. N Engl J Med 2003;349:1064-1075
Full Text | Web of Science | Medline2
Roberts R ,Sigwart U . New concepts in hypertrophic cardiomyopathy. Circulation 2001;104:2249-2252
CrossRef | Web of Science | Medline3
Maron BJ ,McKenna WJ ,Danielson GK , et al. American College of Cardiology/European Society of Cardiology clinical expert document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-1713
CrossRef | Web of Science | Medline4
Spirito P ,Bellone P ,Harris KM ,Bernabo P ,Bruzzi P ,Maron BJ . Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-1785
Full Text | Web of Science | Medline5
Seidman JG ,Seidman C . The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001;104:557-567
CrossRef | Web of Science | Medline6
CardioGenomics home page. (Accessed January 4, 2005, at http://cardiogenomics.med.harvard.edu.)
7
Gollob MH ,Green MS ,Tang AS , et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:1823-1831[Erratum, N Engl J Med 2001;345:552, 2002;346:300.]
Full Text | Web of Science | Medline8
Blair E ,Redwood C ,Ashrafian H , et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001;10:1215-1220
CrossRef | Web of Science | Medline9
Arad M ,Benson DW ,Perez-Atayde AR , et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002;109:357-362
CrossRef | Web of Science | Medline10
Arad M ,Moskowitz IP ,Patel VV , et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 2003;107:2850-2856
CrossRef | Web of Science | Medline11
Nakao S ,Takenaka T ,Maeda M , et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-293
Full Text | Web of Science | Medline12
Danon MJ ,Oh SJ ,DiMauro S , et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981;31:51-57
Web of Science | Medline13
Nishino I ,Fu J ,Tanji K , et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000;406:906-910
CrossRef | Web of Science | Medline14
Sugie K ,Yamamoto A ,Murayama K , et al. Clinopathological features of genetically confirmed Danon disease. Neurology 2002;58:1773-1778
Web of Science | Medline15
Eskelinen EL ,Tanaka Y ,Saftig P . At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 2003;13:137-145
CrossRef | Web of Science | Medline16
Van den Hout H ,Reuser AJ ,Vulto AG ,Loonen MC ,Cromme-Dijkhuis A ,Van der Ploeg AT . Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356:397-398
CrossRef | Web of Science | Medline17
Sachdev B ,Takenaka T ,Teraguchi H , et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-1411
CrossRef | Web of Science | Medline18
Niimura H ,Bachinski LL ,Sangwatanaroj S , et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998;338:1248-1257
Full Text | Web of Science | Medline19
Fatkin D ,MacRae C ,Sasaki T , et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction system disease. N Engl J Med 1999;341:1715-1724
Full Text | Web of Science | Medline20
den Dunnen JT ,Antonarakis SE . No-menclature for the description of human sequence variations. Hum Genet 2001;109:121-124
CrossRef | Web of Science | Medline21
Ausubel FM, Brent R, Kingston RE, et al. Analysis of proteins. In: Current protocols in molecular biology. New York: John Wiley, 1994:10.2.2-10.2.30.
22
Chou TC, Knilans TK. Left ventricular hypertrophy. In: Electrocardiography in clinical practice: adult and pediatric. 4th ed. Philadelphia: W.B. Saunders, 1996:37-53.
23
Morita H ,DePalma SR ,Arad M , et al. Molecular epidemiology of hypertrophic cardiomyopathy. Cold Spring Harb Symp Quant Biol 2002;67:383-388
CrossRef | Web of Science | Medline24
Maron BJ . Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-1320
CrossRef | Web of Science | Medline25
Maron BJ ,Gross BW ,Stark SI . Extreme left ventricular hypertrophy. Circulation 1995;92:2748-2748
Web of Science | Medline26
Amato AA . Acid maltase deficiency and related myopathies. Neurol Clin 2000;18:151-165
CrossRef | Web of Science | Medline27
Patel VV ,Arad M ,Moskowitz IP , et al. Electrophysiological characterization and postnatal development of ventricular pre-excitation in a mouse model of cardiac hypertrophy and Wolff-Parkinson-White syndrome. J Am Coll Cardiol 2003;42:942-951
CrossRef | Web of Science | Medline28
Spirito P ,Seidman CE ,McKenna WJ ,Maron BJ . The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-785
Full Text | Web of Science | Medline
- Citing Articles (111)
Citing Articles
1
Bernard J. Gersh, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Rakowski, Christine E. Seidman, Jeffrey A. Towbin, James E. Udelson, Clyde W. Yancy, Alice K. Jacobs, Sidney C. Smith, Jeffrey L. Anderson, Nancy M. Albert, Christopher E. Buller, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Harlan M. Krumholz, Frederick G. Kushner, Rick A. Nishimura, E. Magnus Ohman, Richard L. Page, William G. Stevenson, Lynn G. Tarkington, Clyde W. Yancy. (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. The Journal of Thoracic and Cardiovascular Surgery 142:6, 1303-1338
CrossRef2
Bernard J. Gersh, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Rakowski, Christine E. Seidman, Jeffrey A. Towbin, James E. Udelson, Clyde W. Yancy, Alice K. Jacobs, Sidney C. Smith, Jeffrey L. Anderson, Nancy M. Albert, Christopher E. Buller, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Harlan M. Krumholz, Frederick G. Kushner, Rick A. Nishimura, E. Magnus Ohman, Richard L. Page, William G. Stevenson, Lynn G. Tarkington, Clyde W. Yancy. (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. The Journal of Thoracic and Cardiovascular Surgery 142:6, e153-e203
CrossRef3
Z. Cheng, Q. Cui, Z. Tian, H. Xie, L. Chen, L. Fang, K. Zhu, Q. Fang. (2011) Danon disease as a cause of concentric left ventricular hypertrophy in patients who underwent endomyocardial biopsy. European Heart Journal
CrossRef4
P. Garcia-Pavia, M. E. Vazquez, J. Segovia, C. Salas, P. Avellana, M. Gomez-Bueno, C. Vilches, M. E. Gallardo, R. Garesse, J. Molano, B. Bornstein, L. Alonso-Pulpon. (2011) Genetic basis of end-stage hypertrophic cardiomyopathy. European Journal of Heart Failure 13:11, 1193-1201
CrossRef5
Bernard J. Gersh, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Rakowski, Christine E. Seidman, Jeffrey A. Towbin, James E. Udelson, Clyde W. Yancy. (2011) 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. Journal of the American College of Cardiology
CrossRef6
Bernard J. Gersh, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Rakowski, Christine E. Seidman, Jeffrey A. Towbin, James E. Udelson, Clyde W. Yancy. (2011) 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology
CrossRef7
Daniela Miani, Matthew Taylor, Luisa Mestroni, Federica D'Aurizio, Nicoletta Finato, Marina Fanin, Silvana Brigido, Alessandro Proclemer. (2011) Sudden Death Associated With Danon Disease in Women. The American Journal of Cardiology
CrossRef8
Maria J. Oliva-Sandoval, Carmen Muñoz-Esparza, Esperanza García-Molina, María Sabater, Juan R. Gimeno, Mariano Valdés. (2011) Hypertrophic cardiomyopathy or storage cardiomyopathy? Role of genetics to predict outcome. International Journal of Cardiology 151:3, 380-381
CrossRef9
Richard P. Davis, Cathelijne W. van den Berg, Simona Casini, Stefan R. Braam, Christine L. Mummery. (2011) Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development. Trends in Molecular Medicine 17:9, 475-484
CrossRef10
A. V. Postma, V. M. Christoffels, C. R. Bezzina. (2011) Developmental aspects of cardiac arrhythmogenesis. Cardiovascular Research 91:2, 243-251
CrossRef11
Thomas Scheffold, Stephan Waldmüller, Konstantin Borisov. (2011) A case of familial hypertrophic cardiomyopathy emphasizes the importance of parallel screening of multiple disease genes. Clinical Research in Cardiology 100:7, 627-628
CrossRef12
Wei Zhang, Hong Wang, Lei Zhang, Jun Yao, Pengyuan Yang. (2011) Large-scale assignment of N-glycosylation sites using complementary enzymatic deglycosylation. Talanta 85:1, 499-505
CrossRef13
B. G. Song, J. R. Park, J. C. Nah. (2011) Fabry's disease cardiomyopathy. Internal Medicine Journal 41:6, 505-506
CrossRef14
Minen Federico, Cont Gabriele, De Cunto Angela, Martelossi Stefano, Ventura Alessandro, Maggiore Giuseppe, Faletra Flavio, Gasparini Paolo, Cassandrini Denise. (2011) Delayed diagnosis of glycogen storage disease type III. Journal of Pediatric Gastroenterology and Nutrition1
CrossRef15
Min Xie, Cyndi R Morales, Sergio Lavandero, Joseph A Hill. (2011) Tuning flux: autophagy as a target of heart disease therapy. Current Opinion in Cardiology 26:3, 216-222
CrossRef16
Wessel P. Brouwer, Sabine J. van Dijk, Ger J. M. Stienen, Albert C. van Rossum, Jolanda van der Velden, Tjeerd Germans. (2011) The development of familial hypertrophic cardiomyopathy: from mutation to bedside. European Journal of Clinical Investigation 41:5, 568-578
CrossRef17
Sarah-Louise Cottinet, Anne-Marie Bergemer-Fouquet, Annick Toutain, Frédérique Sabourdy, Zoha Maakaroun-Vermesse, Thierry Levade, Alain Chantepie, François Labarthe. (2011) Danon disease: intrafamilial phenotypic variability related to a novel LAMP-2 mutation. Journal of Inherited Metabolic Disease 34:2, 515-522
CrossRef18
Nina Ghosh, Haissam Haddad. (2011) Recent progress in the genetics of cardiomyopathy and its role in the clinical evaluation of patients with cardiomyopathy. Current Opinion in Cardiology 26:2, 155-164
CrossRef19
Rahul C. Deo, Calum A. MacRae. (2010) Clinical Screening and Genetic Testing. Clinics in Laboratory Medicine 30:4, 775-784
CrossRef20
Barry J. Maron, William C. Roberts, Carolyn Y. Ho, Carrie Kitner, Tammy S. Haas, Gregory B. Wright, Nader Moazami, David S. Feldman. (2010) Profound Left Ventricular Remodeling Associated With LAMP2 Cardiomyopathy. The American Journal of Cardiology 106:8, 1194-1196
CrossRef21
Hiroyuki Morita, Ryozo Nagai, J. G. Seidman, Christine E. Seidman. (2010) Sarcomere Gene Mutations in Hypertrophy and Heart Failure. Journal of Cardiovascular Translational Research 3:4, 297-303
CrossRef22
Jibin Zhou, Hind Lal, Xiongwen Chen, Xiying Shang, Jianliang Song, Yingxin Li, Risto Kerkela, Bradley W. Doble, Katrina MacAulay, Morgan DeCaul, Walter J. Koch, John Farber, James Woodgett, Erhe Gao, Thomas Force. (2010) GSK-3α directly regulates β-adrenergic signaling and the response of the heart to hemodynamic stress in mice. Journal of Clinical Investigation 120:7, 2280-2291
CrossRef23
Shawyntee M. Vertilus, Stephanie L. Austin, Kimberly S. Foster, Keri E. Boyette, Deeksha S. Bali, Jennifer S. Li, Priya S. Kishnani, Stephanie Burns Wechsler. (2010) Echocardiographic manifestations of Glycogen Storage Disease III: Increase in wall thickness and left ventricular mass over time. Genetics in Medicine 12:7, 413-423
CrossRef24
Heart Failure Society of America. (2010) Section 17: Genetic Evaluation of Cardiomyopathy
. Journal of Cardiac Failure 16:6, e180-e194
CrossRef25
F. Weidemann, A. Linhart, L. Monserrat, J. Strotmann. (2010) Cardiac challenges in patients with Fabry disease. International Journal of Cardiology 141:1, 3-10
CrossRef26
Tetsuo Konno, Stephen Chang, Jonathan G Seidman, Christine E Seidman. (2010) Genetics of hypertrophic cardiomyopathy. Current Opinion in Cardiology 25:3, 205-209
CrossRef27
Cordula M Wolf, Charles I Berul. 2010. Molecular Genetics of Cardiac Arrhythmias. .
CrossRef28
Wojciech Braksator, Barbara Chybowska, Marek Kuch, Miroslaw Dluzniewski. (2010) Caracterización no invasiva de un caso de enfermedad de Danon. Revista Española de Cardiología 63:4, 493-495
CrossRef29
Thomas E Callis, Brian C Jensen, Karen E Weck, Monte S Willis. (2010) Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. Expert Review of Molecular Diagnostics 10:3, 329-351
CrossRef30
Ali J. Marian. (2010) Hypertrophic cardiomyopathy: from genetics to treatment. European Journal of Clinical Investigation 40:4, 360-369
CrossRef31
James B. Seward, Grace Casaclang-Verzosa. (2010) Infiltrative Cardiovascular Diseases. Journal of the American College of Cardiology 55:17, 1769-1779
CrossRef32
Moslemi, Ali-Reza, Lindberg, Christopher, Nilsson, Johanna, Tajsharghi, Homa, Andersson, Bert, Oldfors, Anders, . (2010) Glycogenin-1 Deficiency and Inactivated Priming of Glycogen Synthesis. New England Journal of Medicine 362:13, 1203-1210
Full Text33
Christine Chiu, Richard D. Bagnall, Jodie Ingles, Laura Yeates, Marina Kennerson, Jennifer A. Donald, Mika Jormakka, Joanne M. Lind, Christopher Semsarian. (2010) Mutations in Alpha-Actinin-2 Cause Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology 55:11, 1127-1135
CrossRef34
S. Nouira, I. Arfa, I. Kammoun, A. Abid, H. Ouragini, I. Dorboz, W. Ghazouani, S. Ben Fadhel, M.M. Zorgati, S. Ben Ammar, S. Blousa-Chabchoub, S. Kachboura, S. Abdelhak. (2010) Identification of two novel variants in PRKAG2 gene in Tunisian type 2 diabetic patients with family history of cardiovascular disease. Diabetes Research and Clinical Practice 87:2, e7-e10
CrossRef35
Bronwyn Harris, Jean P. Pfotenhauer, Cheri A. Silverstein, Larry W. Markham, Kim Schafer, Vernat J. Exil, Charles C. Hong. (2010) Serial Observations and Mutational Analysis of an Adoptee with Family History of Hypertrophic Cardiomyopathy. Cardiology Research and Practice 2010, 1-4
CrossRef36
Amir Toib, Dorothy K. Grange, Beth A. Kozel, Gregory A. Ewald, Frances V. White, Charles E. Canter. (2010) Distinct Clinical and Histopathological Presentations of Danon Cardiomyopathy in Young Women. Journal of the American College of Cardiology 55:4, 408-410
CrossRef37
Constantinos O'Mahony, Perry Elliott. (2010) Anderson-Fabry Disease and the Heart. Progress in Cardiovascular Diseases 52:4, 326-335
CrossRef38
Danillo Estevam, Wellington Martins. (2010) Cardiomiopatia hipertrófica: ecocardiografia no diagnóstico e prognóstico. Experts in Ultrasound: Reviews and Perspectives 2:3, 112-116
CrossRef39
Carmela D. Tan, E Rene Rodriguez. 2010. Heart, Pericardium, and Blood Vessels. , 949-985.
CrossRef40
Matthew Wheeler, Aleksandra Pavlovic, Emil DeGoma, Heidi Salisbury, Colleen Brown, Euan A. Ashley. (2009) A New Era in Clinical Genetic Testing for Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research 2:4, 381-391
CrossRef41
Ali J. Marian. (2009) Experimental Therapies in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research 2:4, 483-492
CrossRef42
Brendan P. Kelly, Mark W. Russell, James R. Hennessy, Gregory J. Ensing. (2009) Severe Hypertrophic Cardiomyopathy in an Infant with a Novel PRKAG2 Gene Mutation: Potential Differences Between Infantile and Adult Onset Presentation. Pediatric Cardiology 30:8, 1176-1179
CrossRef43
David A. August. (2009) Anesthetic implications of Danon disease. Pediatric Anesthesia 19:10, 1026-1028
CrossRef44
M. K. Rudd, J. Keene, B. Bunke, E. B. Kaminsky, M. P. Adam, J. G. Mulle, D. H. Ledbetter, C. L. Martin. (2009) Segmental duplications mediate novel, clinically relevant chromosome rearrangements. Human Molecular Genetics 18:16, 2957-2962
CrossRef45
Rory O'Hanlon, Dudley J. Pennell. (2009) Cardiovascular Magnetic Resonance in the Evaluation of Hypertrophic and Infiltrative Cardiomyopathies. Heart Failure Clinics 5:3, 369-387
CrossRef46
J. Martijn Bos, Jeffrey A. Towbin, Michael J. Ackerman. (2009) Diagnostic, Prognostic, and Therapeutic Implications of Genetic Testing for Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology 54:3, 201-211
CrossRef47
William T. Festuccia, Mathieu Laplante, Sophie Brûlé, Vanessa P. Houde, Adel Achouba, Dominic Lachance, Maria L. Pedrosa, Marcelo E. Silva, Renata Guerra-Sá, Jacques Couet, Marie Arsenault, André Marette, Yves Deshaies. (2009) Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation. Journal of Molecular and Cellular Cardiology 47:1, 85-95
CrossRef48
Giorgia Esposito, Giorgia Grutter, Fabrizio Drago, Mauro W. Costa, Antonella De Santis, Giovanna Bosco, Bruno Marino, Emanuele Bellacchio, Francesca Lepri, Richard P. Harvey, Anna Sarkozy, Bruno Dallapiccola. (2009) Molecular analysis of PRKAG2 , LAMP2 , and NKX2-5 genes in a cohort of 125 patients with accessory atrioventricular connection. American Journal of Medical Genetics Part A 149A:7, 1574-1577
CrossRef49
Frédérique Sabourdy, Helen Michelakakis, Aris Anastasakis, Virginie Garcia, Irene Mavridou, Michèle Nieto, Marie-Claude Pons, Constantinos Skiadas, Marina Moraitou, Panagiota Manta, Milan Elleder, Thierry Levade. (2009) Danon disease: Further clinical and molecular heterogeneity. Muscle & Nerve 39:6, 837-844
CrossRef50
Óscar Campuzano, Georgia Sarquella-Brugada, Ramón Brugada, Pedro Brugada, Josep Brugada. (2009) Bases genéticas de las arritmias malignas y las miocardiopatías. Revista Española de Cardiología 62:4, 422-436
CrossRef51
Ray E. Hershberger, Joann Lindenfeld, Luisa Mestroni, Christine E. Seidman, Matthew R.G. Taylor, Jeffrey A. Towbin. (2009) Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline. Journal of Cardiac Failure 15:2, 83-97
CrossRef52
Nina Kaludercic, Carlo Reggiani, Nazareno Paolocci. (2009) Genes, Geography and Geometry. The Journal of Molecular Diagnostics 11:1, 12-16
CrossRef53
So-Yeon Park, Dae-Gyun Park, Hyun-Hee Choi, Duck-Hyoung Yoon, Sung-Eun Kim, Jun-Hee Lee, Kyoo-Rok Han, Dong-Jin Oh. (2009) A Case of Suspected Danon Disease Presenting as a Hypertrophic Cardiomyopathy. Journal of Cardiovascular Ultrasound 17:1, 28
CrossRef54
Nobuhiro Dougu, Shuji Joho, Lishen Shan, Takuya Shida, Akira Matsuki, Keiichiro Uese, Keiichi Hirono, Fukiko Ichida, Kortaro Tanaka, Ichizo Nishino, Hiroshi Inoue. (2009) Novel LAMP-2 Mutation in a Family With Danon Disease Presenting With Hypertrophic Cardiomyopathy. Circulation Journal 73:2, 376-380
CrossRef55
Claudia Di Blasi, Laura Jarre, Flavia Blasevich, Patrizia Dassi, Marina Mora. (2008) Danon disease: A novel LAMP2 mutation affecting the pre-mRNA splicing and causing aberrant transcripts and partial protein expression. Neuromuscular Disorders 18:12, 962-966
CrossRef56
N.A.M.E. van der Beek, O.I.I. Soliman, C.I. van Capelle, M.L. Geleijnse, W.B. Vletter, M.A. Kroos, A.J.J. Reuser, I.M.E. Frohn-Mulder, P.A. van Doorn, A.T. van der Ploeg. (2008) Cardiac evaluation in children and adults with Pompe disease sharing the common c.−32-13T>G genotype rarely reveals abnormalities. Journal of the Neurological Sciences 275:1-2, 46-50
CrossRef57
María Sol Rodríguez-Calvo, María Brion, Catarina Allegue, Luis Concheiro, Angel Carracedo. (2008) Molecular genetics of sudden cardiac death. Forensic Science International 182:1-3, 1-12
CrossRef58
O. I. I. Soliman, N. A. M. E. van der Beek, P. A. van Doorn, W. B. Vletter, A. Nemes, B. M. Van Dalen, F. J. ten Cate, A. T. van der Ploeg, M. L. Geleijnse. (2008) Cardiac involvement in adults with Pompe disease. Journal of Internal Medicine 264:4, 333-339
CrossRef59
YVES VAN BELLE, MICHELLE MICHELS, LUC JORDAENS. (2008) Focal AF-ablation after Pulmonary Vein Isolation in a Patient with Hypertrophic Cardiomyopathy Using Cryothermal Energy. Pacing and Clinical Electrophysiology 31:10, 1358-1361
CrossRef60
Roddy McDowell, Jennifer S. Li, Daniel Kelly Benjamin, Claire Morgan, Alison Becker, Priya S. Kishnani, Ronald J. Kanter. (2008) Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease. Genetics in Medicine 10:10, 758-762
CrossRef61
Prinyarat Burusnukul, Emily C. de los Reyes, Jacqueline Yinger, Daniel R. Boué. (2008) Danon Disease: An Unusual Presentation of Autism. Pediatric Neurology 39:1, 52-54
CrossRef62
Radhakrishnan Ramaraj. (2008) Hypertrophic Cardiomyopathy. Cardiology in Review 16:4, 172-180
CrossRef63
C. Geier, K. Gehmlich, E. Ehler, S. Hassfeld, A. Perrot, K. Hayess, N. Cardim, K. Wenzel, B. Erdmann, F. Krackhardt, M. G. Posch, A. Bublak, H. Nagele, T. Scheffold, R. Dietz, K. R. Chien, S. Spuler, D. O. Furst, P. Nurnberg, C. Ozcelik. (2008) Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. Human Molecular Genetics 17:18, 2753-2765
CrossRef64
Siv Fokstuen, Robert Lyle, Analia Munoz, Corinne Gehrig, René Lerch, Andreas Perrot, Karl Josef Osterziel, Christian Geier, Maurice Beghetti, François Mach, Juan Sztajzel, Ulrich Sigwart, Stylianos E. Antonarakis, Jean-Louis Blouin. (2008) A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Human Mutation 29:6, 879-885
CrossRef65
Gianfranco Sinagra, Andrea Di Lenarda, Michele Moretti, Luisa Mestroni, Bruno Pinamonti, Andrea Perkan, Alessandro Salvi, Stylianos Pyxaras, Rossana Bussani, Furio Silvestri, Fulvio Camerini. (2008) The challenge of cardiomyopathies in 2007. Journal of Cardiovascular Medicine 9:6, 545-554
CrossRef66
Iacopo Olivotto, Francesca Girolami, Michael J. Ackerman, Stefano Nistri, J. Martijn Bos, Elisabetta Zachara, Steve R. Ommen, Jeanne L. Theis, Rachael A. Vaubel, Federica Re, Corinna Armentano, Corrado Poggesi, Francesca Torricelli, Franco Cecchi. (2008) Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings 83:6, 630-638
CrossRef67
I. Olivotto, F. Girolami, M. J. Ackerman, S. Nistri, J. M. Bos, E. Zachara, S. R. Ommen, J. L. Theis, R. A. Vaubel, F. Re, C. Armentano, C. Poggesi, F. Torricelli, F. Cecchi. (2008) Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings 83:6, 630-638
CrossRef68
Morita, Hiroyuki, Rehm, Heidi L., Menesses, Andres, McDonough, Barbara, Roberts, Amy E., Kucherlapati, Raju, Towbin, Jeffrey A., Seidman, J.G., Seidman, Christine E., . (2008) Shared Genetic Causes of Cardiac Hypertrophy in Children and Adults. New England Journal of Medicine 358:18, 1899-1908
Full Text69
M Spinazzi, M Fanin, P Melacini, AC Nascimbeni, C Angelini. (2008) Cardioembolic stroke in Danon disease. Clinical Genetics 73:4, 388-390
CrossRef70
F. Javier García Seara, J. Luis Martínez Sande, Belén Cid Álvarez, José Ramón González Juanatey. (2008) Síndrome de Wolff-Parkinson-White y enfermedad de Danon. Medicina Clínica 130:7, 277
CrossRef71
Amelie Nadeau, Christian Therrien, George Karpati, Michael Sinnreich. (2008) Danon disease due to a novel splice mutation in theLAMP2 gene. Muscle & Nerve 37:3, 338-342
CrossRef72
Yen K. Bui, Pierangelo Renella, Julian A. Martinez-Agosto, Anthony Verity, Andranik Madikians, Juan C. Alejos. (2008) Danon disease with typical early-onset cardiomyopathy in a male: Focus on a novel LAMP-2 mutation. Pediatric Transplantation 12:2, 246-250
CrossRef73
Akinori Kimura. (2008) Molecular Etiology and Pathogenesis of Hereditary Cardiomyopathy. Circulation Journal 72:SupplementA, A38-A48
CrossRef74
J. Malcolm O. Arnold, Jonathan G. Howlett, Anique Ducharme, Justin A. Ezekowitz, Martin J. Gardner, Nadia Giannetti, Haissam Haddad, George A. Heckman, Debra Isaac, Philip Jong, Peter Liu, Elizabeth Mann, Robert S. McKelvie, Gordon W. Moe, Anna M. Svendsen, Ross T. Tsuyuki, Kelly O’Halloran, Heather J. Ross, Errol J. Sequeira, Michel White. (2008) Canadian Cardiovascular Society Consensus Conference guidelines on heart failure – 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Canadian Journal of Cardiology 24:1, 21-40
CrossRef75
CRAIG R. ASHER, ALLAN L. KLEIN. 2008. Primary Restrictive, Infiltrative, and Storage Cardiomyopathies. , 259-276.
CrossRef76
ELENA MARRAS, LUIGI SCIARRA, MANUELA BOCCHINO, PIETRO DELISE. (2008) Pacemaker Malfunctions in Danon's Disease. Pacing and Clinical Electrophysiology 31:1, 125-128
CrossRef77
Camillo Autore, Giovanni Quarta, Paolo Spirito. (2007) Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Current Treatment Options in Cardiovascular Medicine 9:6, 431-435
CrossRef78
Rahul Deo, Calum A. MacRae. (2007) The genetics of cardiomyopathies: What clinicians should know. Current Heart Failure Reports 4:4, 229-235
CrossRef79
Zhao Yang, Matteo Vatta. (2007) Danon Disease as a Cause of Autophagic Vacuolar Myopathy. Congenital Heart Disease 2:6, 404-409
CrossRef80
RONNY ALCALAI, JONATHAN G. SEIDMAN, CHRISTINE E. SEIDMAN. (2007) Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics. Journal of Cardiovascular Electrophysiology 0:0, 071004055652012-???
CrossRef81
Matthew R. G. Taylor, Lisa Ku, Dobromir Slavov, Jean Cavanaugh, Mark Boucek, Xiao Zhu, Sharon Graw, Elisa Carniel, Carl Barnes, Dianna Quan, Ryan Prall, Mark A. Lovell, Gary Mierau, Patsy Ruegg, Naresh Mandava, Michael R. Bristow, Jeffrey A. Towbin, Luisa Mestroni, . (2007) Danon disease presenting with dilated cardiomyopathy and a complex phenotype. Journal of Human Genetics 52:10, 830-835
CrossRef82
Alexander J. C. Mittnacht, Christine Moung, Wyman W. Lai. (2007) Massive Cardiac Hypertrophy in a Patient with Danon Disease: An Intraoperative Transesophageal Echocardiographic Evaluation. Anesthesia & Analgesia 105:4, 963-965
CrossRef83
P. Weyrich, F. Machicao, H. Staiger, P. Simon, C. Thamer, J. Machann, F. Schick, A. Guirguis, A. Fritsche, N. Stefan, H.-U. Häring. (2007) Role of AMP-activated protein kinase gamma 3 genetic variability in glucose and lipid metabolism in non-diabetic whites. Diabetologia 50:10, 2097-2106
CrossRef84
Barry J. Maron. (2007) Hypertrophic Cardiomyopathy and Other Causes of Sudden Cardiac Death in Young Competitive Athletes, with Considerations for Preparticipation Screening and Criteria for Disqualification. Cardiology Clinics 25:3, 399-414
CrossRef85
J Martijn Bos, Steve R Ommen, Michael J Ackerman. (2007) Genetics of hypertrophic cardiomyopathy: one, two, or more diseases?. Current Opinion in Cardiology 22:3, 193-199
CrossRef86
Ivan Luptak, Mei Shen, Huamei He, Michael F. Hirshman, Nicolas Musi, Laurie J. Goodyear, Jie Yan, Hiroko Wakimoto, Hiroyuki Morita, Michael Arad, Christine E. Seidman, J.G. Seidman, Joanne S. Ingwall, James A. Balschi, Rong Tian. (2007) Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. Journal of Clinical Investigation 117:5, 1432-1439
CrossRef87
(2007) Barry Joel Maron, MD: A Conversation With the Editor
This series of interviews was underwritten by an unrestricted grant from Bristol-Myers Squibb.. The American Journal of Cardiology 99:9, 1334-1349
CrossRef88
Akiyoshi Ogimoto, Minoru Okubo, Hideki Okayama, Yoon S. Shin, Yoriko Endo, Tetsu Ebara, Katsuji Inoue, Tomoaki Ohtsuka, Hideki Tahara, Toshio Murase, Jistuo Higaki. (2007) A Japanese Patient With Cardiomyopathy Caused by a Novel Mutation R285X in the AGL Gene. Circulation Journal 71:10, 1653-1656
CrossRef89
Suad Catovic, Petar Otasevic. (2007) Danon disease: A case report and literature overview. Srpski arhiv za celokupno lekarstvo 135:3-4, 197-200
CrossRef90
Jeanne L. Theis, J. Martijn Bos, Virginia B. Bartleson, Melissa L. Will, Josepha Binder, Matteo Vatta, Jeffrey A. Towbin, Bernard J. Gersh, Steve R. Ommen, Michael J. Ackerman. (2006) Echocardiographic-determined septal morphology in Z-disc hypertrophic cardiomyopathy. Biochemical and Biophysical Research Communications 351:4, 896-902
CrossRef91
Joanne M Lind, Christine Chiu, Christopher Semsarian. (2006) Genetic basis of hypertrophic cardiomyopathy. Expert Review of Cardiovascular Therapy 4:6, 927-934
CrossRef92
Rafaella M.P. Nascimento, Paulo A. Otto, Arjan P.M. de Brouwer, Angela M. Vianna-Morgante. (2006) UBE2A, Which Encodes a Ubiquitin-Conjugating Enzyme, Is Mutated in a Novel X-Linked Mental Retardation Syndrome. The American Journal of Human Genetics 79:3, 549-555
CrossRef93
Cordula M. Wolf, Charles I. Berul. (2006) Response to the Editor:. Journal of Cardiovascular Electrophysiology 17:9, E6-E6
CrossRef94
Vlad C. Vasile, Steve R. Ommen, William D. Edwards, Michael J. Ackerman. (2006) A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy. Biochemical and Biophysical Research Communications 345:3, 998-1003
CrossRef95
Jörg Stypmann, Paul M.L. Janssen, Jürgen Prestle, Markus A. Engelen, Harald Kögler, Renate Lüllmann-Rauch, Lars Eckardt, Kurt Figura, Jobst Landgrebe, Anna Mleczko, Paul Saftig. (2006) LAMP-2 deficient mice show depressed cardiac contractile function without significant changes in calcium handling. Basic Research in Cardiology 101:4, 281-291
CrossRef96
Yanlin Xing, Fukiko Ichida, Taro Matsuoka, Takeshi Isobe, Yumiko Ikemoto, Takashi Higaki, Tohru Tsuji, Noriyuki Haneda, Atsushi Kuwabara, Rui Chen, Takeshi Futatani, Shinichi Tsubata, Sayaka Watanabe, Kazuhiro Watanabe, Keiichi Hirono, Keiichiro Uese, Toshio Miyawaki, Karla R. Bowles, Neil E. Bowles, Jeffrey A. Towbin. (2006) Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. Molecular Genetics and Metabolism 88:1, 71-77
CrossRef97
Annette K. Ansong, Jennifer S. Li, Eva Nozik-Grayck, Richard Ing, Richard M. Kravitz, Salim F. Idriss, Ronald J. Kanter, Henry Rice, Y T. Chen, Priya S. Kishnani. (2006) Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genetics in Medicine 8:5, 297-301
CrossRef98
Marina Fanin, Anna C. Nascimbeni, Luigi Fulizio, Marco Spinazzi, Paola Melacini, Corrado Angelini. (2006) Generalized Lysosome-Associated Membrane Protein-2 Defect Explains Multisystem Clinical Involvement and Allows Leukocyte Diagnostic Screening in Danon Disease. The American Journal of Pathology 168:4, 1309-1320
CrossRef99
CORDULA M WOLF, CHARLES I BERUL. (2006) Inherited Conduction System Abnormalities-One Group of Diseases, Many Genes. Journal of Cardiovascular Electrophysiology 17:4, 446-455
CrossRef100
Pascal Laforêt, Pascale Richard, Mina Ait Said, Norma Beatriz Romero, Emmanuelle Lacene, Jean-Paul Leroy, Christiane Baussan, Jean-Yves Hogrel, Thomas Lavergne, Karim Wahbi, Bernard Hainque, Denis Duboc. (2006) A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis. Neuromuscular Disorders 16:3, 178-182
CrossRef101
Carolyn Y. Ho, Christine E. Seidman. 2006. Genetics and Heart Failure: Hypertrophic Cardiomyopathy. , 589-606.
CrossRef102
Liviu C. Poliac, Michael E. Barron, Barry J. Maron. (2006) Hypertrophic Cardiomyopathy. Anesthesiology 104:1, 183-192
CrossRef103
W FRISHMAN. (2006) Gender-related Differences in the Clinical Presentation and Outcome of Hypertrophic CardiomyopathyOlivotto I, Maron MS, Adabag AS, et al (Universitaria Careggi, Florence, Italy: Minneapolis Heart Inst; Tufts-New England Med Ctr, Boston) J Am Coll Cardiol 46:480–487, 2005§. Yearbook of Medicine 2006, 341-342
CrossRef104
B THIERS. (2006) Glycogen Storage Diseases Presenting as Hypertrophic CardiomyopathyArad M, Maron BJ, Gorham JM, et al (Harvard Med School, Boston; Minneapolis Heart Inst Found; Univ of Alabama at Birmingham; et al) N Engl J Med 352:362–372, 2005§. Yearbook of Dermatology and Dermatologic Surgery 2006, 208-209
CrossRef105
Min Xu, Xiaoying Li, Ji-Guang Wang, Pengfei Du, Jie Hong, Weiqiong Gu, Yifei Zhang, Guang Ning. (2005) Glucose and lipid metabolism in relation to novel polymorphisms in the 5′-AMP-activated protein kinase γ2 gene in Chinese. Molecular Genetics and Metabolism 86:3, 372-378
CrossRef106
Michael J. Ackerman, Sara L. Van Driest, Martijn Bos. (2005) Are Longitudinal, Natural History Studies the Next Step in Genotype-Phenotype Translational Genomics in Hypertrophic Cardiomyopathy?* *Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 46:9, 1744-1746
CrossRef107
JAVED EHTISHAM, HUGH WATKINS. (2005) Is Wolff-Parkinson-White Syndrome a Genetic Disease?. Journal of Cardiovascular Electrophysiology 16:11, 1258-1262
CrossRef108
Ferhaan Ahmad, J.G. Seidman, Christine E. Seidman. (2005) THE GENETIC BASIS FOR CARDIAC REMODELING. Annual Review of Genomics and Human Genetics 6:1, 185-216
CrossRef109
Franco Cecchi, Magdi H Yacoub, Iacopo Olivotto. (2005) Hypertrophic cardiomyopathy in the community: why we should care. Nature Clinical Practice Cardiovascular Medicine 2:7, 324-325
CrossRef110
(2005) Glycogen Storage Diseases and Cardiomyopathy. New England Journal of Medicine 352:24, 2553-2553
Full Text111
Barbara Burwinkel, John W. Scott, Christoph Bührer, Frank K.H. van Landeghem, Gerald F. Cox, Callum J. Wilson, D. Grahame Hardie, Manfred W. Kilimann. (2005) Fatal Congenital Heart Glycogenosis Caused by a Recurrent Activating R531Q Mutation in the γ2-Subunit of AMP-Activated Protein Kinase (PRKAG2), Not by Phosphorylase Kinase Deficiency. The American Journal of Human Genetics 76:6, 1034-1049
CrossRef
- Letters
